Drug Discovery Established: June 2003 Current Edition: Volume 7
Aims and Scope • Drug Discovery enables time-pressured physicians to stay abreast of key advances and opinion in drug discovery. • Drug Discovery comprises balanced and comprehensive articles written by leading authorities addressing the most important and salient developments in the drug discovery field.
• Drug Discovery endeavours to support leading industry professionals in continuously developing their knowledge, effectiveness and productivity. The editorial policy has been designed to encourage discussion among this peer group.
• Comprehensive bibliographies for each article mean that Drug Discovery is an informative and valuable reference tool for use throughout the year.
Structure and Format • Drug Discovery is an annual journal comprising review articles, case reports, practice guides, theoretical discussions and original research. •
•
The structure of each edition of the publication comprises section categories determined by the Editor. The degree of coverage assigned to each category is the decision of the Editor, and in part reflects the views of the Advisory Board. Articles are fully referenced, providing a comprehensive review of existing knowledge and opinion. • Each edition of Drug Discovery is also replicated in full online at
www.touchbriefings.com
Editorial Expertise Drug Discovery is supported by various levels of expertise: • • • •
Peer Review • •
•
Guidance from an Editorial Board consisting of leading authorities from a variety of drug discovery disciplines. Invited contributors are recognised authorities from their respective fields.
Peer review – conducted by experts appointed for their experience and knowledge of a specific topic. An experienced team of Editors and Technical Editors.
On submission, all articles are assessed by the Editor to determine their suitability for inclusion and appropriateness for peer review.
The Editor, following consultation with either a member of the Advisory Board or the author(s), identifies appropriate reviewers, who are selected on the basis of their specialist knowledge in the relevant area.
Following review, papers are either accepted without modification or returned to the author(s) to incorporate required changes. The Editor reserves the right to accept or reject any proposed amendments.
Submissions and Instructions to Authors • • • •
Reprints
All articles included in Drug Discovery are available as reprints (minimum order 1,000). Please contact Fergus Brunning at
fergus.brunning@
touchbriefings.com or T: +44 (0) 20 7452 5285.
Distribution and Readership Drug Discovery is distributed annually through controlled circulation to senior professionals in the field.
Subscriptions Drug Discovery is published anually and is available on subscription. Subscription rates for 2010 are as follows: Full Institutional (online and print): €180 (Europe), US$225 (the Americas); Full Institutional (online only): €170 (Europe), US$210 (the Americas); Full Personal (online and print): €80 (Europe), US$100 (the Americas); Full Personal (online only): €70 (Europe), US$85 (the Americas). Professionals in the drug discovery field qualify for free subscriptions. For further information contact Louise Monrose at
louise.monrose@
touchbriefings.com or T: +44 (0) 20 7452 5319.
Copyright and Permission Touch Briefings, a Touch Group plc company, is the sole owner of all articles and other materials that appear in Drug Discovery, unless otherwise stated. Permission to reproduce an article, either in full or in part, should be sought from the publication’s Editor.
Online
www.touchbriefings.com provides clinicians and other industry professionals with a free resource of thousands of articles from over 40 quarterly, bi-annual and annual titles spanning 22 healthcare and pharmaceutical specialities.
About Touch Briefings Touch Briefings publishes a rich and diverse portfolio of fully referenced review journals across the clinical and pharmaceutical arenas. Through this portfolio of over 40 print titles and dedicated industry websites, Touch Briefings aims to assist in the education and practice of healthcare and pharmaceutical professionals. n
Contributors are identified and invited by the Editor with the support of the Technical Editors and guidance from the Advisory Board. Following acceptance of an invitation, the author(s) and Editor formalise the working title and scope of the article. Subsequently, the Editor provides an ‘Instruction to Authors’ document and additional submission details.
The Editor is always keen to hear from leading authorities wishing to discuss potential submissions, and will give due consideration to any proposals. Please contact the Editor for further details. The ‘Instruction to Authors’ information is available for download at
www.touchbriefings.com
2
© TOUCH BRIEFINGS 2010
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84